Cargando…

Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa

INTRODUCTION: The rapid clearance of factor IX necessitates frequent intravenous administrations to achieve effective prophylaxis for patients with hemophilia B. Subcutaneous administration has historically been limited by low bioavailability and potency. Dalcinonacog alfa was developed using a rati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nichols, Timothy C., Levy, Howard, Merricks, Elizabeth P., Raymer, Robin A., Lee, Martin L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592742/ https://www.ncbi.nlm.nih.gov/pubmed/33112889 http://dx.doi.org/10.1371/journal.pone.0240896

Ejemplares similares

Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Activity measurements of dalcinonacog alfa
por: Williams, Stella C., et al.
Publicado: (2020)

Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients
por: Faraj, Alan, et al.
Publicado: (2023)

Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models
por: Markusic, David M., et al.
Publicado: (2017)

Coagulation Factor IX for Hemophilia B Therapy 
por: Orlova, N. A., et al.
Publicado: (2012)

Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test – Demonstrated in vitro and ex vivo
por: Madsen, Daniel Elenius, et al.
Publicado: (2017)

Porcine and Canine von Willebrand Factor and von Willebrand Disease: Hemostasis, Thrombosis, and Atherosclerosis Studies
por: Nichols, Timothy C., et al.
Publicado: (2010)

Development of Methods for the Selective Measurement of the Single Amino Acid Exchange Variant Coagulation Factor IX Padua
por: Weber, Alfred, et al.
Publicado: (2018)

Real-World Use of Albutrepenonacog Alfa, A Recombinant Coagulation Factor IX Albumin Fusion Protein, for Personalized Prophylaxis in Japanese Individuals With Hemophilia B: A Case Series
por: Nagao, Azusa, et al.
Publicado: (2023)

Oxidized LDL and Fructosamine Associated with Severity of Coronary Artery Atherosclerosis in Insulin Resistant Pigs Fed a High Fat/High NaCl Diet
por: Nichols, Timothy C., et al.
Publicado: (2015)

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease
por: Fishbane, Steven, et al.
Publicado: (2019)

Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B
por: Fukutake, Katsuyuki, et al.
Publicado: (2019)

Effect of Thrombomodulin Alfa on Disseminated Intravascular Coagulation in Patients with Lung Cancer
por: Nakano, Kentaro, et al.
Publicado: (2017)

Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce
por: Herzog, Roland W., et al.
Publicado: (2017)

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Probing activation‐driven changes in coagulation factor IX by mass spectrometry
por: Freato, Nadia, et al.
Publicado: (2021)

Confirmation of warfarin resistance of naturally occurring VKORC1 variants by coexpression with coagulation factor IX and in silico protein modelling
por: Müller, Elisabeth, et al.
Publicado: (2014)

Compensated pathogenic variants in coagulation factors VIII and IX present complex mapping between molecular impact and hemophilia severity
por: Marín, Òscar, et al.
Publicado: (2019)

Pharmacological Differentiation of Thrombomodulin Alfa and Activated Protein C on Coagulation and Fibrinolysis In Vitro
por: Tanaka, Kosuke, et al.
Publicado: (2018)

Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product
por: Zacchi, Lucia F., et al.
Publicado: (2021)

Bioavailability of IgG Administered by the Subcutaneous Route
por: Berger, Melvin, et al.
Publicado: (2013)

Characterization of IXINITY® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph
por: Monroe, Dougald M., et al.
Publicado: (2016)

The first EGF domain of coagulation factor IX attenuates cell adhesion and induces apoptosis
por: Ishikawa, Tomomi, et al.
Publicado: (2016)

Ribosome profiling of HEK293T cells overexpressing codon optimized coagulation factor IX
por: Alexaki, Aikaterini, et al.
Publicado: (2020)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
por: Rodríguez-Lojo, R., et al.
Publicado: (2010)

Long-Acting Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Children: Results of a Phase 3 Trial
por: Kenet, Gili, et al.
Publicado: (2016)

Can velmanase alfa be the next widespread potential therapy for alpha-mannosidosis?
por: Abdul Ghani, Sundus, et al.
Publicado: (2023)

Preclinical Evaluation of Ureidosulfamate Carbonic Anhydrase IX/XII Inhibitors in the Treatment of Cancers
por: Williams, Kaye J., et al.
Publicado: (2019)

Recombinant biosynthesis of functional human growth hormone and coagulation factor IX in transgenic soybean seeds
por: da Cunha, Nicolau Brito, et al.
Publicado: (2014)

Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies
por: Alexaki, Aikaterini, et al.
Publicado: (2019)

Fusion of engineered albumin with factor IX Padua extends half‐life and improves coagulant activity
por: Lombardi, Silvia, et al.
Publicado: (2021)

Coagulation factors II, V, VII, IX, X and XI and mortality – a cohort study
por: Yap, Eng Soo, et al.
Publicado: (2023)

Prothrombin Time and Coagulation Factor IX as Hemostatic Risk Markers for Legg– Calvé–Perthes Disease
por: Hernández-Zamora, Edgar, et al.
Publicado: (2023)

The Pharmacokinetics of Medetomidine Administered Subcutaneously during Isoflurane Anaesthesia in Sprague-Dawley Rats
por: Kint, Leila T., et al.
Publicado: (2020)

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
por: Tahir, Stephen K., et al.
Publicado: (2023)

Darbepoetin alfa is more potent in vivo and can be administered less frequently than rHuEPO
por: Egrie, J, et al.
Publicado: (2002)

Safety, pharmacokinetics and CNS distribution of tralesinidase alfa administered via intracerebroventricular infusion to juvenile cynomolgus monkeys
por: Pinkstaff, Jason, et al.
Publicado: (2023)

Benefit Profile of Thrombomodulin Alfa Combined with Antithrombin Concentrate in Patients with Sepsis-Induced Disseminated Intravascular Coagulation
por: Murao, Atsushi, et al.
Publicado: (2022)

Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients
por: Prasad, Bhanu, et al.
Publicado: (2020)

Absorption Kinetics of Subcutaneously Administered Ceftazidime in Hypoperfused Guinea Pigs
por: Ebihara, Tsuyoshi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_up1samn8003mjminfg55stdshl